Science in Sport PLC


Science in Sport PLC

Consumer GoodsFood Producers
  • Price (GBX)36.98
  • Today's Change-0.02 / -0.05%
  • Shares traded29.80k
  • 1 Year change-29.56%
  • Beta1.1248
Data delayed at least 20 minutes, as of Sep 25 2020 11:34 BST.
More ▼

Profile data is unavailable for this security.

About the company

Science in Sport plc is engaged in developing, manufacturing and marketing sports nutrition products for professional athletes and sports enthusiasts. The Company's product lines include SiS GO isotonic powders and gels, which are digestible carbohydrates for use during exercise; SiS hydration products, which include SiS GO Hydro tablets and SiS GO Electrolyte powders; SiS GO Bars, which include cereal-based food bars; SiS REGO range, which includes drinks and protein bars for recovery after training, and SiS Protein, which is a whey protein range for lean muscle development. The Company offers products in sport categories, including cycling, running, gym, team sports, triathlon and rowing. The Company's products include SiS GO Energy, SiS REGO Rapid Recovery, SiS WHEY20, SiS Whey Protein, SiS GO Isotonic Energy Gel, SiS Elite Team SKY and GO Energy Bar. The Company's subsidiaries include SiS (Science in Sport) Limited, SiS APAC Pty Limited and Science in Sport Inc.

  • Revenue in GBP (TTM)50.57m
  • Net income in GBP-5.62m
  • Incorporated2013
  • Employees142.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
MiLOC Group Limited1.56m-3.82m26.36m6.00------16.87-0.0476-0.04760.0195-0.05810.77321.5042.06---203.42-140.25----33.9641.02-263.08-218.440.0936-61.11----44.650.9406-7.05--25.76--
ImmuPharma PLC77.93k-6.12m28.57m17.00--3.68--366.60-0.0413-0.04130.00050.03150.0108--0.32134,584.12-84.70-95.81-94.83-115.35-----7,857.81-5,223.63---13.580.0051---4.12-15.8615.03---20.99--
ReNeuron Group Plc6.07m-11.41m29.01m61.00--2.19--4.78-0.3587-0.35870.19070.41540.2338--7.9399,426.23-43.99-31.41-60.00-35.82-----188.16-1,128.08----0.0619--12,277.55189.1620.46--14.30--
Collagen Solutions PLC4.01m-3.37m29.61m48.00--1.64--7.38-0.0074-0.00740.0090.04030.19582.942.61---16.43-9.92-19.17-11.0068.5272.21-83.93-55.281.10-7.570.0697---3.3832.75-102.00--39.87--
ValiRx Plc0.00-2.44m34.86m11.00--7.31-----0.2281-0.22810.000.08140.00----0.00-60.45-73.95-76.47-107.97-----------233.180.0804------44.43--7.59--
Futura Medical plc.31.78k-5.52m35.00m13.00--16.52--1,101.38-0.0262-0.02620.00010.00860.0058--10.152,444.62-99.86-58.40-168.03-68.33-----17,369.76-4,623.323.17--0.00-----6.27-51.67--33.26--
IXICO PLC8.69m692.00k39.09m68.0056.854.5740.674.500.01460.01460.18390.18150.8393--3.72127,794.106.68-15.498.52-22.1965.5758.927.96-21.70----0.00--40.17--164.67------
Hemogenyx Pharmaceuticals PLC0.00-1.45m43.36m7.00---------0.004-0.0040.00-0.0010.00----0.00-86.77---96.78-------------98.261.38------6.07------
Integumen PLC1.48m-2.27m45.27m9.00--30.66--30.59-0.0222-0.02220.01430.0130.21935.562.02---33.65-74.84-40.42-161.1565.2763.51-153.45-837.701.03-70.590.1453--200.37316.07-55.12--10.27--
Fusion Antibodies PLC3.90m-697.00k48.33m47.00--8.72--12.41-0.0316-0.03160.17630.21780.63427.294.8882,872.34-11.35-6.71-13.28-7.7545.4948.38-17.89-11.412.49-75.640.0732--78.5233.7744.87--57.63--
OptiBiotix Health PLC744.88k-2.12m49.07m10.00--9.18--65.88-0.0248-0.02480.00870.06080.09897.561.5274,488.00-28.11-14.81-30.44-15.5952.7364.52-284.39-266.912.23-28.800.122--44.84---10.32--252.06--
Science in Sport PLC50.57m-5.62m49.99m142.00--1.01--0.9884-0.0458-0.04580.41210.3680.8494.285.09---9.43-13.25-11.15-15.4843.9151.63-11.11-17.631.57-232.000.0233--137.23--4.37------
e-Therapeutics plc456.00k-2.35m61.29m16.00--8.74--134.40-0.0087-0.00870.00170.01670.0742--16.8928,500.00-38.18-38.13-41.44-40.68100.00100.00-514.69-6,730.00----0.0151--936.36--41.31---38.97--
Immunodiagnostic Systems Hldgs PLC39.35m3.35m66.20m295.0019.801.168.201.680.11620.11621.371.980.56522.373.78133,379.704.81-6.805.54-7.6444.1648.668.51-12.253.70--0.0587--2.17-2.81320.607.32-5.62-8.73
OKYO Pharma Ltd0.00-1.21m73.98m4.00---------0.0021-0.00210.00-0.00020.00----0.00-227.94---1,482.32----------------------67.69------
Data as of Sep 25 2020. Currency figures normalised to Science in Sport PLC's reporting currency: UK Pound GBX

Institutional shareholders

55.27%Per cent of shares held by top holders
HolderShares% Held
BennBridge Ltd.as of 27 Apr 202016.21m12.00%
Aviva Investors Global Services Ltd.as of 27 Apr 202014.62m10.82%
J.O. Hambro Capital Management Ltd.as of 31 Dec 201910.13m7.50%
Otus Capital Management Ltd.as of 31 Dec 20197.55m5.59%
River & Mercantile Asset Management LLPas of 15 Jan 20206.72m4.98%
Miton Asset Management Ltd.as of 27 Jun 20196.12m4.53%
Canaccord Genuity Wealth Ltd.as of 30 Jan 20194.43m3.28%
Legal & General Investment Management Ltd.as of 07 Sep 20204.04m2.99%
Baillie Gifford & Co.as of 31 Dec 20193.79m2.80%
S.W. Mitchell Capital LLPas of 30 Apr 20191.05m0.78%
More ▼
Data from 31 Mar 2020 - 25 Aug 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.